Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Mofest vs Avelox (Moxifloxacin) in Healthy Subjects
NCT04873570Phase 1Completed
- Sponsor
- University of Karachi
- Start
- May 2021
- Primary completion
- Jun 2021
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of moxifloxacin in bacterial infection (2 arms), sponsored by University of Karachi. Primary endpoints: Maximum Plasma Concentration, Time to Reach Maximum Plasma Concentration and 1 more. Started May 2021; status: completed.
02
Drugs
moxifloxacin
03
Conditions
bacterial infection
Beyond the preview
Go deeper on NCT04873570.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04873570.